Brea Lipe, MD: Hello and welcome to this OncLive My Treatment Approach program titled, "Recent Advances in the Treatment of Multiple Myeloma at First Relapse." I am Brea Lipe, and I'm the associate professor at the department of medicine at the University of Rochester in New York, and the director of the multiple myeloma program. I am joined today by my colleague, Dr Peter Forsberg, and I would like to welcome him to introduce himself.
Peter Forsberg, MD: Hi, Dr Lipe. I'm Peter Forsberg, I'm associate professor at the University of Colorado and the director of our myeloma program. So happy to participate in the conversation today. So welcome and thanks for joining us. And today we're going to discuss recent updates in the treatment of relapse/refractory multiple myeloma, and its impact on clinical practice. So, we'll be doing that by presenting two hypothetical patient cases, and then discussing our treatment approach to illustrate how we incorporate recent data in our clinical practice. So, let's go ahead and get started. So as Dr. Lipe said, our- the name of our presentation today is my treatment approach, recent advances in the treatment of multiple myeloma and early relapse specifically. And this is a patient profile to start with. So, this is a patient who was diagnosis, a 63-year-old female. This was in January 2017 when she presented with anemia, hypercalcemia, and after being evaluated by her primary care physician was found to have acute onset severe rib pain. And then radiographs had evidence of non-displaced rib fractures, bilaterally. Workup showed an IgG kappa multiple myeloma, and subsequent bone marrow biopsy demonstrated 35% clonal plasma cells. And cytogenetics included FISH, which showed a gain of chromosome 1q. So, she underwent a PET CT, which confirmed lytic disease throughout the spine and multiple rib lesions, and was treated initially with RVD, or lenalidomide, revlimid, bortezomib, Velcade, and dexamethasone starting in February 2017. Completed five cycles, achieved a very good partial response and then proceeded with autologous stem cell transplant with melphalan 200 milligrams meter squared conditioning, and after recovery was started on lenalidomide maintenance. So unfortunately, at follow up, on four years follow up state reevaluation was found to have progressive disease and at that time was started on isatuximab, carfilzomib, dexamethasone as second line therapy in May of 2021. So as of last follow up, the patient continues on the isatuximab, carfilzomib and dexamethasone in a very good partial response and is tolerating therapy well without issue. So, I believe, I think that brings us into discussion. In terms of my initial impressions of this case, I think it's a pretty standard consideration. A patient in 2017 diagnosed with new myeloma in their early to mid-60s. Treated with RVD induction, has long been a standard of care initial combination. And then followed by an autologous stem cell transplant and lenalidomide maintenance. And we know that based on recent data that patients with this combination of induction followed by transplant, followed by maintenance can have really stable long-lasting remissions potentially. So, patient experiencing relapse several years in- following the initiation of their induction, is pretty common. So, I think this is a pretty common scenario for us to be dealing with. And I think that the main consideration that's sort of become more prominent in the last couple of years is, do we start still with RVD or would we think about using a four-drug combination in this patient for initial induction, incorporating a CD38 monoclonal antibody like daratumumab plus RVD. So, I think that's probably the biggest practice change that might inform how we treat this patient that'd be a little different than what we might have been doing in 2017. Certainly, something that's does not uniform necessarily across myeloma providers, but is appropriate consideration, I think. And I- but otherwise I think still considering stem cell transplant and often lenalidomide based maintenance remains our kind of primary standard of care. I guess, I'd ask you if you had any additional thoughts. And then, I know the question of defining relapse, how we identify a progressive event. Defining with biochemical versus clinical relapse and sort of characteristics and standard criteria that define those. Maybe sort of delineating how you define progressive disease for [myeloma] in your practice.
Brea Lipe, MD: So, I always think it's fun to kind of look back and we see these patients in our practice, and they were started on therapy in 2017 or whenever that might have been, and to think about how our practice has changed. And I would agree that quads are something that I use a lot more frequently now, pretty much uniformly for induction in patients who are able. The only other thing that I thought was different about this case, that I might have done something different about even back in 2017 was the gain of 1q and that portending some higher risk features. And I often even back then used a more combination maintenance approach for those patients with higher risk cytogenetics. But regardless the patient did really well after transplant with just lenalidomide maintenance, which is great. And so, I think that it does come to this interesting question of what biochemical versus clinical relapse is and how those are defined. And so, the goal in my practice is to always have biochemical relapses because by the time we have clinical relapses, that's really defined by those CRAB criteria or symptomatic myeloma. So, my goal is to avoid symptoms because those can be compounding over time and can increase the toxicities of our therapy. So, my goal is always to catch it before it gets to the point where the patients are beginning to have suffering and side effects. And what we know is that biochemical relapse, so that's defined by the International Myeloma Working Group, the relapse criteria, and it's a biochemical relapse when we don't have those classic myeloma symptoms. And that's pretty much the standard IMWG relapse criteria, which includes changes of 25% to the paraprotein, as long as it's at least a rise of 0.5 and changes to the involved versus uninvolved light chains of at least 10. And so, there are pretty standard criteria for that, that you can follow over time for patients who achieve a CR, which this patient might not have. But anytime you start to see the reemergence of a paraprotein that's also a biochemical relapse. And so, I think that it's important to keep close track of our patients. I like to follow my patients in their labs, even when they're several years out closely, just so that I know that when they're starting to have these biochemical relapses, so I can intervene before they get a clinical relapse. We know that on average patients with biochemical relapses will have symptomatic development of myeloma defining events within about five months. So, I think that just highlights the need to identify those biochemical relapses. When you intervene on that is- can be up for debate but constitutes a biochemical relapse it's relevant for treatment versus those patients who will just kind of slowly progress biochemically and might be- might not progress within five months symptomatically. So, I think it's just important to keep an idea on.
See the original post here:
Patient Profile 1: A 63-Year-Old Female with Relapsed Multiple Myeloma - OncLive
- Glowing embryonic gecko hand and otherworldly slime mold amaze in winning microscope photos - Livescience.com - October 13th, 2022
- Sierra Space, UC San Diego Partner to Develop the First Stem Cell Research Institute in Space - Business Wire - October 4th, 2022
- Second-Line BCL Treatment Landscape Shifts From ASCT to CAR T-Cell Therapy - Targeted Oncology - October 4th, 2022
- CellResearch Corporation reports positive results of DFU trial - Labiotech.eu - September 25th, 2022
- University of Colorado's ocular stem cell and regenerative research program recognized - Ophthalmology Times - September 8th, 2022
- RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies - GlobeNewswire - August 22nd, 2022
- Stem Cell Therapy: Update and Clinical Research 2022 - August 14th, 2022
- The engineer who teaches our bodies to heal themselves - EL PAS USA - July 19th, 2022
- Control in Healthcare: History and Reclamation of Bodily Autonomy - Non Profit News - Nonprofit Quarterly - July 19th, 2022
- This Simple Fish May Have Been One of the First Vertebrates - The Scientist - July 11th, 2022
- How Tumor Cells Use Mitochondria to Keep Growing - July 3rd, 2022
- Nearly 75 Percent Of Veterinarians Concerned That Frequent Injections Could Cause Joint Damage - Horse Racing News - Paulick Report - July 3rd, 2022
- OEDIT Announces Recipients of Collaborative Infrastructure Grant - Colorado Office of Economic Development and International Trade - June 22nd, 2022
- Politics Briefing: Conservative leadership race is intense, Bergen says, but she expects party unity once it's over - The Globe and Mail - June 13th, 2022
- Maine health care workers to appeal order to disclose their names in vaccine mandate lawsuit - Press Herald - June 4th, 2022
- America's return to the 19th century - York Dispatch - June 4th, 2022
- Top 10 Most Popular Stem Cell Treatments of 2022 - April 19th, 2022
- Will Smith's Slap at the Oscars Awakens the World to Alopecia Areata - University of Colorado Anschutz Medical Campus - April 19th, 2022
- Northern Colorado Doctor Researching New Treatment Options ... - December 24th, 2021
- Christmas Wish: 4-year-old just wants life-saving treatment for her twin brother - FOX 31 Denver - December 24th, 2021
- Breakthrough infections might not be a big transmission risk. Heres the evidence. - WBEZ - October 16th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Stem Cell Therapy Market Size, Top Key Players, Applications, Business Statistics, Trends and Forecast 2021-2027 The Bisouv Network - The Bisouv... - February 7th, 2021
- More on deadly blizzards | TheFencePost.com - Fence Post - February 7th, 2021
- 'A heart of gold': Rick Schwartz remembered for his commitment to family, community - CTV News - November 13th, 2020
- Alex Trebek died of pancreatic cancer think twice before saying he lost his battle with the disease - MarketWatch - November 13th, 2020
- Culprit Mutations, Risky (Neandertal) Variants, Genomic Analysis App: COVID-19 Updates - Bio-IT World - October 7th, 2020
- Stem Cell Therapy Market Size, Analytical Overview, Key Players, Growth Factors, Demand, Trends And Forecast to 2027 - thedailychronicle.in - September 30th, 2020
- Cancer Stem Cells Market is Thriving Worldwide 2020-2027 | Top Companies Merck KGaA, ONCOMED PHARMACEUTICALS INC, Bionomics, MacroGenics, Inc.,... - September 9th, 2020
- 27 De-Stressing Vegan Products to Help You Get Through The Rest of 2020 - VegNews - September 9th, 2020
- THE BONDS OF FRIENDSHIP: OXFORD AND SUNWAY - The Star Online - September 9th, 2020
- Colorados juvenile prisons have avoided COVID-19 outbreaks, but advocates worry about the future - The Denver Post - May 30th, 2020
- Future Leader Winner Using Technology To Solve The Problems He Sees - CBS Denver - May 30th, 2020
- SONDERMANN | Is it time to send a scientist to the Senate? - coloradopolitics.com - April 18th, 2020
- 5 Things to Know About Hemp-CBD In Pet Products - The Fresh Toast - April 18th, 2020
- Alone, together: Isolation in the name of health is familiar - Coloradoan - March 24th, 2020
- Stem Cell Therapy Colorado - thriveMD Denver & Vail, CO - March 20th, 2020
- Little Tissue, Big Mission: Beating Heart Tissues to Ride Aboard The ISS - Newswise - March 9th, 2020
- Denver Regenerative Medicine & Stem Cell Therapy - March 1st, 2020
- 5 most popular innovation stories in Houston this week - InnovationMap - January 5th, 2020
- Chiropractor Denver Announces Hormone Replacement Therapy Colorado Springs to Transform Life of Aging People - Press Release - Digital Journal - November 24th, 2019
- Cord Blood Banking Services Market size with global investment, top companies analysis, new business developments and forecast 2025 - Montana Ledger - November 16th, 2019
- Stem Cell Therapy - Boulder, Colorado | Boulder Biologics |Jason Glowney, MD | Stem Cells - Denver, Colorado | PRP | Regenerative Medicine | EPAT |... - May 20th, 2019
- Stem Cells and Hearing Loss - Sound Relief Hearing Center - May 1st, 2019
- Stem Cell Therapy - Boulder, Colorado | Boulder Biologics ... - April 20th, 2019
- Stem Cell Therapy for Joint Pain and Soft Tissue, Colorado - April 12th, 2019
- Stem Cells from Fat vs. Bone Marrow Best Sources for ... - April 7th, 2019
- CROM Stem Cell Therapy- Denver, Colorado - March 27th, 2019
- Gene expression in stem cells | Data Nuggets - March 7th, 2019
- Denver Stem Cell | Area's Leading Stem Cell Doctors - February 22nd, 2019
- Stem Cell Therapy - Colorado Springs Orthopaedic Group - January 16th, 2019
- Using Stem Cells to Treat Sepsis - Stem Cell Centers, Colorado - November 28th, 2018
- Stem Cell Fraud | Colorado Stem Cell Therapy - November 23rd, 2018
- Colorado Stem Cell Therapy | Home - October 1st, 2018
- FAQ | Colorado Stem Cell Therapy - October 1st, 2018
- Stem Cell Therapy | Spine & Joint Solutions - Colorado Springs - July 29th, 2018
- In Depth About Regenerative Therapy | Regen Colorado - July 25th, 2018
- Pepsi: Aborted Baby Cells in Drink Research | Colorado ... - July 15th, 2018
- Stem Cell Therapy in Colorado | Aspen Integrative Medicine - June 23rd, 2018
- Stem Cell Therapy Denver Colorado - Colorado Rehabilitation - June 18th, 2018
- Stem Cell PRP Therapy | Colorado Stem Cell Therapy - June 18th, 2018
- Stem Cell Therapy - Colorado Springs Orthopedics - October 14th, 2017
- Top Stem Cell Therapy Clinic in Vail & Denver, Colorado ... - September 25th, 2017
- 'Little Frankenstein,' conceived so Minnesota doctors could save sister, is now a happy teen - Minneapolis Star Tribune - June 25th, 2017
- What happens when scientists leave their labs to experiment with politics? - Los Angeles Times - June 21st, 2017
- Regenexx: injections soon will replace orthopedic surgery - Broomfield Enterprise - June 21st, 2017
- How a simple cheek swab can save a life - FOX31 Denver - June 4th, 2017
- Ground broken on new $US65 million facility at Colorado State University - Horsetalk - June 4th, 2017
- SpaceX to launch CU-built heart, bone health experiments to space station - CU Boulder Today - June 4th, 2017
- Translational Medicine Institute launched at Colorado State University - Source - June 4th, 2017
- Giraffe 'sneakers' in use at the Cheyenne Mountain Zoo! - KKTV 11 News - May 24th, 2017
- For the first time ever, researchers produced lab-grown blood stem cells - Colorado Springs Gazette - May 24th, 2017
- Chattanooga Student Surprised to be a Gift of Life Donor - WDEF News 12 - May 24th, 2017
- Is Autologous Heamatopoietic Stem Cell Transplantation Still Viable for MS? - LWW Journals - May 19th, 2017
- Stem Cell Transplants May Work for MS, Study Says - LWW Journals (blog) - April 20th, 2017
- 'Priming' protein boosts stem cell response to injury, promotes healing - FierceBiotech - April 20th, 2017
- Overcoming Opioids: The quest for less addictive drugs - Colorado Springs Gazette - April 20th, 2017
- Climbing mountains for cancer research - The Wilton Bulletin - April 20th, 2017
- Australian of the Year Alan Mackay-Sim on the advantage of being 'an interested scientist' - The Sydney Morning Herald - April 9th, 2017
- Northern Colorado Surgeon Releases Three Year Results of Bone Marrow Stem Cell Treatment - PR Web (press release) - April 5th, 2017